Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.
Nicholas ReboldMichael J RybakAbdalhamid M LagnfSara AlosaimyDana HolgerKatie E BarberJulie Ann JustoKayla AntoszTravis J CarlsonJeremy J FrensMark J BiagiWesley D KufelWilliam J MooreNicholas J MercuroBrian R RauxMichael Joseph RybakPublished in: Open forum infectious diseases (2021)
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.
Keyphrases
- multidrug resistant
- end stage renal disease
- gram negative
- newly diagnosed
- ejection fraction
- chronic kidney disease
- pseudomonas aeruginosa
- peritoneal dialysis
- prognostic factors
- drug resistant
- acinetobacter baumannii
- cystic fibrosis
- escherichia coli
- pulmonary hypertension
- staphylococcus aureus
- patient reported outcomes